| Identification | Back Directory | [Name]
2-Pyridinecarbothioamide, N-2-pyridinyl- | [CAS]
39122-38-8 | [Synonyms]
NSC 185058
2-Pyridinecarbothioamide, N-2-pyridinyl-
N-(Pyridin-2-yl)pyridine-2-carbothioamide | [Molecular Formula]
C11H9N3S | [MOL File]
39122-38-8.mol | [Molecular Weight]
215.27 |
| Chemical Properties | Back Directory | [Melting point ]
82 °C(Solv: ethanol, 70% (64-17-5)) | [Boiling point ]
378.2±40.0 °C(Predicted) | [density ]
1.323±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,Room temperature | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 2.5 mg/ml | [form ]
A crystalline solid | [pka]
8.76±0.70(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
NSC 185058 is an inhibitor of ATG4B, a major cysteine protease. Inhibition of ATG4B using NSC 185058 markedly attenuates autophagic activity[1]. | [in vivo]
NSC185058 is an ATG4B antagonist. ATG4B stimulates autophagy by promoting autophagosome formation through reversible modification of ATG8. Inclusion of the ATG4B inhibitor NSC185058 enhances the anti-tumor activity of radiation therapy (RT). NSC185058 decreases glioblastoma (GBM) cell tumorigenicity, and enhances the anti-tumor activity of RT when applied to orthotopic GBM xenograft models[1]. | [storage]
4°C, protect from light | [References]
[1] Huang T, et al. MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma. Cancer Cell. 2017 Dec 11;32(6):840-855.e8. DOI:10.1016/j.ccell.2017.11.005 |
|
|